Kolexia
Puy Herve
Biologie médicale
Hôpital Louis-Mourier
Colombes, France
150 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Porphyries Porphyrie aigüe intermittente Anémie Protoporphyrie érythropoïétique Porphyrie érythropoïétique Carences en fer Insuffisance rénale chronique Maladies du rein Anémie par carence en fer

Industries

Vifor
7 collaboration(s)
Dernière en 2022
COMM Santé
4 collaboration(s)
Dernière en 2021
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Management of erythropoietic protoporphyria with cholestatic liver disease: A case report.
Molecular genetics and metabolism reports   31 octobre 2023
Quantification of Urine and Plasma Porphyrin Precursors Using LC-MS in Acute Hepatic Porphyrias: Improvement in Routine Diagnosis and in the Monitoring of Kidney Failure Patients.
Clinical chemistry   04 octobre 2023
Evaluation of iron metabolism in hospitalized COVID-19 patients.
Clinica chimica acta; international journal of clinical chemistry   05 août 2023
Reversible atransferrinemia in a patient with chronic enteropathy: is transferrin mandatory for iron transport?
Biochemia medica   15 décembre 2022
Porfirias hereditarias en niños
EMC. Pediatria   01 décembre 2022
Neglected Comorbidity of Chronic Heart Failure: Iron Deficiency.
Nutrients   05 août 2022
A neglected comorbidity of chronic heart failure: iron deficiency.
Annales de biologie clinique   30 juin 2022
Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action.
Journal of internal medicine   03 mai 2022
ABCB6 polymorphisms are not overly represented in patients with porphyria.
Blood advances   11 avril 2022
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease: A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral β-A-T87Q Globin Vector (LentiGlobin BB305 Drug Product)
Essai Clinique (Bluebird)   05 avril 2022